The American Heart Association and the American College of Cardiology have released the first clinical practice guideline specifically for acute pulmonary embolism (PE), introducing a new Acute Pulmonary Embolism Clinical Category system to define severity and guide treatment strategies. Published simultaneously in Circulation and JACC, the guideline emphasizes prompt diagnosis and treatment to reduce mortality and complications from this life-threatening condition, which affects approximately 470,000 people annually in the U.S., with about 1 in 5 high-risk patients dying.
The new classification system categorizes patients into five groups (A through E) based on symptom severity and risk of adverse outcomes. Categories A and B include patients with no or mild symptoms and low risk, who may be safely discharged from the emergency department. Categories C through E encompass higher-risk patients requiring hospitalization or critical care. This system aims to help clinicians tailor treatment based on individual patient needs and available resources.
Risk factors for acute PE include recent surgery or hospitalization, trauma, prolonged immobility, pregnancy, obesity, cancer, and blood clotting disorders. The guideline recommends assessing these factors when evaluating patients with symptoms such as shortness of breath, chest pain, rapid heartbeat, fainting, or dizziness. For patients with low or intermediate probability of PE, a D-dimer blood test is advised; if elevated or if clinical probability is high, imaging with computed tomography pulmonary angiography (CTPA) is the standard diagnostic test.
Treatment primarily involves anticoagulants, with direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban preferred over warfarin due to better safety and ease of use, except during pregnancy when low-molecular-weight heparin is recommended. For higher-risk patients (Categories D-E), advanced treatments like clot-dissolving drugs or mechanical removal may be necessary. The guideline also details appropriate sedation, ventilation, and circulatory support for critically ill patients.
Follow-up care includes early communication within one week of discharge, a three-month visit to reassess anticoagulation duration, and long-term monitoring for chronic thromboembolic pulmonary disease. Screening for depression, anxiety, and PTSD is suggested, and patients are encouraged to engage in early walking and use compression socks during long travel. The guideline is endorsed by eight other healthcare organizations, including the American College of Emergency Physicians and the Society for Vascular Medicine.
For more information, the full guideline is available in Circulation at https://www.ahajournals.org/journal/circ and in JACC at https://www.jacc.org/.
